Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle.

Humans Hepatitis B virus / genetics Nucleic Acids / therapeutic use Prospective Studies DNA, Viral / genetics Hepatitis B, Chronic / drug therapy Virus Replication Hepatitis B RNA RNA, Viral / analysis
Alternative splicing Chronic hepatitis Chronic infection HBV HBV pregenomic RNA Liver disease Viral circulating forms Viral cycle Viral genome diversity Viral hepatitis

Journal

Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 02 03 2022
accepted: 01 07 2022
pubmed: 5 8 2022
medline: 30 11 2022
entrez: 4 8 2022
Statut: ppublish

Résumé

Besides the prototypical hepatitis B virus (HBV) infectious particle, which contains a full-length double-stranded DNA (flDNA), additional circulating virus-like particles, which carry pregenomic RNA (pgRNA), spliced1RNA (sp1RNA) or spliced-derived DNA (defDNA) forms have been described. We aimed to determine the level of these four circulating forms in patients and to evaluate their impact on viral lifecycle. Chronic HBV untreated patients (n = 162), included in the HEPATHER cohort, were investigated. Pangenomic qPCRs were set up to quantify the four circulating forms of HBV nucleic acids (HBV Hierarchical clustering individualized two clusters of HBV Besides the critical role of HBV replication in circulating HBV Patients were included from a prospective multicenter French national cohort (ANRS CO22 HEPATHER, NCT01953458).

Sections du résumé

BACKGROUND BACKGROUND
Besides the prototypical hepatitis B virus (HBV) infectious particle, which contains a full-length double-stranded DNA (flDNA), additional circulating virus-like particles, which carry pregenomic RNA (pgRNA), spliced1RNA (sp1RNA) or spliced-derived DNA (defDNA) forms have been described. We aimed to determine the level of these four circulating forms in patients and to evaluate their impact on viral lifecycle.
METHODS METHODS
Chronic HBV untreated patients (n = 162), included in the HEPATHER cohort, were investigated. Pangenomic qPCRs were set up to quantify the four circulating forms of HBV nucleic acids (HBV
RESULTS RESULTS
Hierarchical clustering individualized two clusters of HBV
CONCLUSION CONCLUSIONS
Besides the critical role of HBV replication in circulating HBV
CLINICAL TRIAL REGISTRATION BACKGROUND
Patients were included from a prospective multicenter French national cohort (ANRS CO22 HEPATHER, NCT01953458).

Identifiants

DOI: 10.1007/s12072-022-10389-6 PMID: 35927368
pubmed: 35927368
doi: 10.1007/s12072-022-10389-6
pii: 10.1007/s12072-022-10389-6
doi:

Substances chimiques

Nucleic Acids 0
DNA, Viral 0
RNA 63231-63-0
RNA, Viral 0

Banques de données

ClinicalTrials.gov
['NCT01953458']

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1259-1272

Subventions

Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : ECTZ 103985
Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : ECTZ 163186
Organisme : FRM
ID : EQU202003010517

Informations de copyright

© 2022. Asian Pacific Association for the Study of the Liver.

Références

European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370–398
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015;479–480:672–686
pubmed: 25759099 doi: 10.1016/j.virol.2015.02.031
Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol 2018;92:e00798-18
doi: 10.1128/JVI.00798-18
Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 2017;9(3):56
doi: 10.3390/v9030056
Kouwaki T, Fukushima Y, Daito T, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol 2016;7:335
pubmed: 27630638 pmcid: 5005343 doi: 10.3389/fimmu.2016.00335
Pol JG, Lekbaby B, Redelsperger F, et al. Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-alpha-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 2015;29:1879–1889
pubmed: 25630972 doi: 10.1096/fj.14-258715
Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000;105:55–60
pubmed: 10619861 pmcid: 382588 doi: 10.1172/JCI8098
Soussan P, Pol J, Garreau F, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008;198:218–225
pubmed: 18532883 doi: 10.1086/589623
Kremsdorf D, Lekbaby B, Bablon P, et al. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021, 70:2373–2382
Bayliss J, Lim L, Thompson AJ, et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol 2013;59:1022–1028
pubmed: 23811301 doi: 10.1016/j.jhep.2013.06.018
Duriez M, Mandouri Y, Lekbaby B, et al. Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity. J Hepatol 2017;67:687–699
pubmed: 28600137 pmcid: 6433284 doi: 10.1016/j.jhep.2017.05.025
Lim CS, Sozzi V, Littlejohn M, et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7
Redelsperger F, Lekbaby B, Mandouri Y, et al. Production of hepatitis B defective particles is dependent on liver status. Virology 2012;431:21–28
pubmed: 22664356 doi: 10.1016/j.virol.2012.05.008
Soussan P, Tuveri R, Nalpas B, et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003;38:343–348
pubmed: 12586301 doi: 10.1016/S0168-8278(02)00422-1
Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017;61:e0080-17
doi: 10.1128/AAC.00680-17
Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B. Clin Infect Dis 2021;72:202–211
pubmed: 31912157 doi: 10.1093/cid/ciaa013
Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 2021;74:2395–2409
pubmed: 34133774 doi: 10.1002/hep.32018
Goncalves A, Lemenuel-Diot A, Cosson V, et al. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383–392
pubmed: 33074571 doi: 10.1111/jvh.13425
Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016;213:224–232
pubmed: 26216905 doi: 10.1093/infdis/jiv397
Kaewdech A, Tangkijvanich P, Sripongpun P, et al. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961–2971
pubmed: 32668074 doi: 10.1111/liv.14606
Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 2019;19:53
pubmed: 30991954 pmcid: 6469196 doi: 10.1186/s12876-019-0966-4
Liu Y, Xue J, Liao W, et al. Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy. J Clin Gastroenterol 2020;54:e73–e82
pubmed: 32604147 pmcid: 7458089 doi: 10.1097/MCG.0000000000001376
Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 2021;73:2167–2179
pubmed: 33159329 doi: 10.1002/hep.31616
van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66–76
pubmed: 25132147 doi: 10.1002/hep.27381
van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610–619
pubmed: 32052503 pmcid: 7383601 doi: 10.1111/jvh.13272
Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65:700–710
pubmed: 27245431 doi: 10.1016/j.jhep.2016.05.029
Xiang Y, Yang Y, Chen P, et al. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine (Baltimore) 2021;100:e27433
pubmed: 34622857 doi: 10.1097/MD.0000000000027433
Xie Y, Li M, Ou X, et al. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856–867
pubmed: 34292372 pmcid: 8370917 doi: 10.1007/s00535-021-01812-0
Yu XQ, Wang MJ, Yu DM, et al. Comparison of serum hepatitis B virus rna levels and quasispecies evolution patterns between entecavir and pegylated-interferon MONO-treatment in chronic hepatitis B patients. J Clin Microbiol 2020;58:e00075-20
pubmed: 32554476 pmcid: 7448659 doi: 10.1128/JCM.00075-20
Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212–224
pubmed: 32100261 doi: 10.1007/s12072-020-10015-3
Ma G, Lou B, Lv F, et al. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: “Loss of HBsAg” maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264–269
pubmed: 31730814 doi: 10.1016/j.cca.2019.10.049
Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5’RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol 2020;73:40–51
pubmed: 32087349 doi: 10.1016/j.jhep.2020.01.028
Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018;25:1038–1047
pubmed: 29633430 doi: 10.1111/jvh.12908
Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4
pubmed: 33407619 pmcid: 7789711 doi: 10.1186/s12985-020-01471-2
Zhou Y, Peng Y, Yuan H, et al. Serum hepatitis B virus ribonucleic acid and its influencing factors in chronic hepatitis B. Adv Clin Exp Med 2021;30:361–367
pubmed: 33928768 doi: 10.17219/acem/131756
Prakash K, Rydell GE, Larsson SB, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86
pubmed: 29764511 pmcid: 5952638 doi: 10.1186/s12985-018-0994-7
Wang ML, Liao J, Ye F, et al. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688–3696
pubmed: 32949174 doi: 10.1002/jmv.26529
Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog 2020;16:e1008945
pubmed: 33079954 pmcid: 7575114 doi: 10.1371/journal.ppat.1008945
Yu G, Chen R, Zheng S, et al. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerg Microbes Infect 2022;11:775–785
pubmed: 35220917 pmcid: 8920369 doi: 10.1080/22221751.2022.2045874
Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 2015;63:1093–1102
pubmed: 26143443 doi: 10.1016/j.jhep.2015.06.023
Garcia-Garcia S, Cortese MF, Tabernero D, et al. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: different quasispecies? World J Gastroenterol 2021;27:7144–7158
pubmed: 34887634 pmcid: 8613647 doi: 10.3748/wjg.v27.i41.7144
Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol 2018;68:847–849
pubmed: 29113914 doi: 10.1016/j.jhep.2017.10.030
Liu Y, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination. Hepatology 2020;71:463–476
pubmed: 31278760 doi: 10.1002/hep.30844
Yao Y, Yang B, Chen Y, et al. RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element. J Virol 2019;93:e02161-18
pubmed: 30626666 pmcid: 6401439 doi: 10.1128/JVI.02161-18

Auteurs

Jules Sotty (J)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Pierre Bablon (P)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Bouchra Lekbaby (B)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Jérémy Augustin (J)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.
Université Paris-Est Créteil, Département de Pathologie, Hôpital Henri Mondor, Créteil, France.

Morgane Girier-Dufournier (M)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Lucas Langlois (L)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Céline Dorival (C)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de santé publique, Hôpital Saint-Antoine, AP-HP, Paris, France.

Fabrice Carrat (F)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de santé publique, Hôpital Saint-Antoine, AP-HP, Paris, France.

Stanislas Pol (S)

Université de Paris, AP-HP, Département d'hépatologie, Hôpital Cochin, Paris, France.

Hélène Fontaine (H)

Université de Paris, AP-HP, Département d'hépatologie, Hôpital Cochin, Paris, France.

Nazim Sarica (N)

Institut de Génétique Humaine, Université de Montpellier, Laboratoire de Virologie Moléculaire CNRS-UMR9002, Montpellier, France.

Christine Neuveut (C)

Institut de Génétique Humaine, Université de Montpellier, Laboratoire de Virologie Moléculaire CNRS-UMR9002, Montpellier, France.

Chantal Housset (C)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Dina Kremdsorf (D)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.

Aurélie Schnuriger (A)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Département de Virologie, GHU Paris-Est, Paris, France.

Patrick Soussan (P)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche de Saint Antoine (CRSA), Paris, France. patrick.soussan@inserm.fr.
Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Département de Virologie, GHU Paris-Est, Paris, France. patrick.soussan@inserm.fr.
ORCID: 0000-0003-2706-7371

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Virus › Virus de l'hépatite › Hepadnaviridae › Orthohepadnavirus › Virus de l'hépatite B › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN viral › Diversity of the nucleic acid forms of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite B chronique › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Hépatite › Hépatites virales humaines › Hépatite B › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › Diversity of the nucleic acid forms of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN viral › Diversity of the nucleic acid forms of...